2014 a memorable year for M&A activity in pharma sector

15 January 2015

2014 was a busy year for merger and acquisition activity in the pharmaceutical industry, but will be remembered particularly for the mega billion dollar deals that were abandoned.

In total, 2014 saw the announcement (and mostly completion) of 137 M&A transactions, compared with 122 in 2013 and 131 in 2012, as tracked by The Pharma Letter. Values were also considerably higher. The Financial Times reported that more than $250 billion of deals have been struck in 2014 by pharma companies.

According to a Burrill Media report released last week, companies' completed a record $355.3 billion in transactions in 2014, up from $131.9 billion in 2013 and surpassing the previous record of $235.5 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK